Breast cancer cells
Breast cancer cells: Due to their relative rarity, male breast cancer patients have often been excluded from clinical trials. The FDA encourages the industry to change this policy.

Image source: National Cancer Institute / Georgetown Lombardi Comprehensive Cancer Center

Draft guidance

FDA: Include male breast cancer patients in trials

In its latest draft guidance, the U.S. Food and Drug Administration (FDA) encourages inclusion of males in breast cancer clinical trials.

Many therapies are only approved for women and further data may be necessary to support labeling indications for men

Richard Pazdur

Historically, males either have not been included in clinical trials for drugs to treat breast cancer or inclusion of males in those trials has been very limited; when finalized, the draft guidance will provide clarity for industry regarding clinical development of drugs to treat breast cancer in male patients. 

“Less than one percent of all breast cancer cases occur in men, but men are more likely to be diagnosed at an older age and have a more advanced stage of disease. As breast cancer in men is rare, they have typically not been included in clinical trials for breast cancer treatment. This has led to a lack of data, so their treatment is generally based upon studies and data collected in women. While some FDA-approved treatments are gender-neutral in their indication, many therapies are only approved for women and further data may be necessary to support labeling indications for men. Today we issued a draft guidance encouraging the inclusion of male patients in breast cancer clinical trials. When finalized, the recommendations in the draft guidance will provide clarity for industry regarding how additional data to support efficacy and safety for male patients with breast cancer can be generated through a variety of trial designs using different data sources, including studies using real-world data,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.

Recommended article

Photo

Fact-checking

Inherited cancer and genetic testing - looking beyond the myths

Cancer is a genetic disease caused by abnormal changes over time to genes that control cell function, typically starting in a single cell (an acquired mutation) and often not linked to an inherited genetic mutation. In other words, most cancers happen by chance. Only about 5 to 10 percent of cancers are due to an inherited genetic mutation, says Monique Lubaton, MGC, CGC, cancer genetic counselor…

“We hope that the recommendations in the draft guidance issued today will, when finalized, encourage drug development for the treatment of male breast cancer and ultimately, provide additional FDA-approved treatment options for patients.” 

The draft guidance 'Male Breast Cancer: Developing Drugs for Treatment' can be found on the FDA website.


Source: U.S. Food and Drug Administration (FDA)

27.08.2019

Read all latest stories

Related articles

Photo

Feasibility study

Liquid biopsy to complement early breast cancer screening

Investigators from the Biomedical Research Institute of Malaga [(IBIMA)-CIMES-UMA, Malaga Spain] and collaborators have published the first pilot study to examine the use of a non-invasive liquid…

Photo

Under pressure

Breast tissue stiffening promotes cancer development

A study provides new insight into how the stiffening of breast tissue plays a role in breast cancer development. By examining how mammary cells respond in a stiffness-changing hydrogel, bioengineers…

Photo

Hot helper

Can oolong tea prevent breast cancer?

In a recent study published in the journal Anticancer Research, Saint Louis University scientists, together with a visiting scientist from Fujian Medical University in China, have discovered evidence…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH